Dr. Richard Scheller on Scientific Rigor, Genetics, and the Evolution of Drug Development @googleventures
Dr. Richard Scheller on Scientific Rigor, Genetics, and the Evolution of Drug Development  @googleventures
Uploaded March 2021 | Updated November 2026, 3 hours ago
Richard and I recently spent an hour together discussing today's startup landscape in science and medicine, and he compared Genentech's culture to what he sees as a concerning drop in scientific rigor inside some new companies. He attributes this to the intense pressure to publish, coupled with the increase in venture activity in life sciences.

Read more: gv.com/news/richard-scheller-genetics-drug-development
Dr. Richard Scheller on Scientific Rigor, Genetics, and the Evolution of Drug DevelopmentGitLab’s IPO: On Culture, Tech, and Long-Term ThinkingAI Builders San FranciscoSprint: TuesdayInstagram’s Ian Spalter on Globally-Minded DesignWelcoming Our Newest Advisor: Katie Dill, Former Design Lead at Airbnb and LyftStartup Lab workshop: Web front-end latencyRedpanda: Alex Gallego on the Future of Data StreamingNetflix’s Steve Johnson on Pushing the Design Industry ForwardAera Therapeutics: Akin Akinc on Building a Biotech Company & Breaking Barriers in Genomic MedicineA conversation with OpenEvidence founder Zachary ZeiglerStackOne: Founders Romain Sestier and Guillaume Lebedel on the Future of Integrations
GV (Google Ventures) |

Dr. Richard Scheller on Scientific Rigor, Genetics, and the Evolution of Drug Development

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER